CommercialCoverageMedium impact
JAK2, MPL, and CALR Testing for Myeloproliferative Neoplasms 2.02.53
Excellus BlueCross BlueShield·Hematology, Oncology, Pathology·Lab Tests (pathology)
Effective date
Mar 19, 2026
We identified it
Jun 20, 2026
Summary
Excellus BlueCross BlueShield has established new medical necessity criteria for JAK2, MPL, and CALR genetic testing used to diagnose myeloproliferative neoplasms (blood cancers). The policy specifies that testing is only covered when specific clinical criteria are met and secondary causes have been evaluated, with broad molecular panel testing considered investigational.
Action Required
Before March 19, 2026: Billing team must update prior authorization processes to verify that JAK2, MPL, and CALR genetic testing orders meet all specified medical necessity criteria including clinical findings suggestive of myeloproliferative neoplasms and evaluation for secondary causes. Providers must document that testing is performed on blood or bone marrow samples and avoid ordering broad molecular panel testing which will be denied as investigational.